Compounded Tirzepatide & Tesamorelin Body Composition Stack

The stack is two separately compounded, physician-prescribed injectables shipped together: one vial of compounded tirzepatide for appetite control and total weight loss, and one vial of tesamorelin for targeted visceral fat loss and lean-muscle support. There is a single formulation of each — no dosage tiers to pick from. Your physician provides the per-injection instructions for both.

Tirzepatide works on gut-brain signalling to reduce hunger and slow digestion, which drives the total weight loss. Tesamorelin prompts your pituitary to release growth hormone in its natural rhythm, which raises IGF-1, preferentially breaks down visceral fat, and helps preserve muscle. One decides how much you lose; the other shapes what you lose.

Yes, under medical supervision. They act on different systems (gut hormone receptors vs. the growth hormone axis) and have no known direct interaction. Because growth hormone can slightly reduce insulin sensitivity while tirzepatide improves it, your physician monitors fasting glucose and IGF-1 with periodic bloodwork. Both are prescribed together only after a licensed physician reviews your health history.

Separately, on different schedules. Tirzepatide is one subcutaneous injection per week (belly, thigh, or upper arm). Tesamorelin is one subcutaneous injection into the abdomen each night at bedtime, ideally on an empty stomach, to work with your body's natural night-time growth hormone pulse. On your weekly tirzepatide day you simply do both.

Up to 25–40% of weight lost on a GLP-1 alone can be lean mass if nothing is done to protect it. Tesamorelin's growth hormone signalling helps your body hold onto muscle in a deficit, and combined with adequate protein and resistance training two to three times a week, helps more of your loss come from fat.

Visceral fat is the deep fat packed around your liver and other organs. It is more metabolically active and more strongly linked to insulin resistance, fatty liver, and cardiovascular risk than the fat under your skin. Tesamorelin reduced visceral fat by about 18% in 26 weeks in its FDA-reviewed trials — a selectivity diet and GLP-1s alone do not have.

Most patients notice reduced appetite within 1–2 weeks, and better sleep and recovery from tesamorelin within the first few weeks. Waist and body-composition changes typically become visible at 6–8 weeks, with meaningful weight loss building over 3–6 months. Visceral fat reductions in tesamorelin trials peaked at 26 weeks.

Tesamorelin has been shown to reduce liver fat and improve triglycerides in clinical studies, and tirzepatide improves blood sugar and insulin sensitivity. Many patients see liver enzymes and lipid panels improve; your physician can track these on follow-up labs.

Tirzepatide: nausea, constipation, or mild GI discomfort, most common in the first weeks and usually easing over time. Tesamorelin: injection-site redness or itching, temporary joint aches, mild fluid retention, or tingling in the hands. Serious side effects are rare; your physician reviews warnings with you before prescribing.

Tesamorelin is FDA-approved (as Egrifta, 2010) for reducing excess abdominal fat in HIV-associated lipodystrophy; its use here is off-label. Compounded tirzepatide and compounded tesamorelin are prepared by a licensed U.S. pharmacy and are not FDA-approved products; the FDA does not evaluate compounded drugs for safety, effectiveness, or quality. FDA-approved tirzepatide medications (Zepbound, Mounjaro) are available by prescription.

Anyone who is pregnant, breastfeeding, or planning pregnancy; anyone with active cancer or a history of malignancy; anyone with a pituitary disorder or prior pituitary surgery; anyone with a personal or family history of medullary thyroid carcinoma or MEN2; anyone with a history of pancreatitis; and anyone with type 1 diabetes. Your physician screens for these during your assessment.

Tirzepatide slows digestion, which can affect timing and absorption of some oral medications, and may require adjustments if you take insulin or sulfonylureas. Tesamorelin can interact with glucocorticoids and other hormone therapies. Your physician reviews everything you take and orders baseline and follow-up labs (fasting glucose or A1c, IGF-1, lipids) to keep the stack safe.

Keep both vials refrigerated at 36-46°F (2-8°C), protected from light, and never frozen. Once a tesamorelin vial is reconstituted, use it within the window stated in your in-use guidance. Follow the instructions that ship with your order.

Appetite typically returns within a few weeks of stopping tirzepatide, and in tesamorelin trials visceral fat gradually returned after treatment was withdrawn. Patients who keep up protein intake, resistance training, and sleep habits built during treatment are most likely to hold their results. Your physician can help you plan a taper or a maintenance approach.

Tirzepatide alone reduces total weight but is non-selective about where fat comes from and does nothing to protect muscle. Synthetic HGH (somatropin) adds muscle support but does so by injecting growth hormone directly, bypassing your pituitary's feedback regulation — which is why it carries higher risks of insulin resistance, fluid retention, and joint pain, and works against tirzepatide's blood-sugar benefits. Tesamorelin prompts your own pituitary to release growth hormone in its natural rhythm, preserves that feedback loop, and is the only GHRH analog with FDA-reviewed evidence of visceral fat reduction — which is why it is the one we pair with tirzepatide.